Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Curent Deferred Tax Liability Curent Deferred Tax Liability Current Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

IGC Pharma (IGC) Long-Term Investments (2016 - 2025)

IGC Pharma has reported Long-Term Investments over the past 12 years, most recently at $25000.0 for Q3 2025.

Quarterly Long-Term Investments changed N/A to $25000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $25000.0 through Sep 2025, changed N/A year-over-year, with the annual reading at $12000.0 for FY2021, 9.09% up from the prior year.
Long-Term Investments was $25000.0 for Q3 2025 at IGC Pharma, up from $11000.0 in the prior quarter.
Over five years, Long-Term Investments peaked at $25000.0 in Q3 2025 and troughed at $11000.0 in Q2 2021.